Are generic versions of Viagra available, and what about Revatio?
Generic Viagra (sildenafil for erectile dysfunction) is available because sildenafil’s patents have expired. Generic Revatio (sildenafil for pulmonary arterial hypertension) also exists, but the key is that the drug is the same active ingredient (sildenafil) with different approved uses and dosing formulations depending on the product.
What is Revatio specifically used for?
Revatio is sildenafil approved for pulmonary arterial hypertension (PAH). Sildenafil for PAH is typically prescribed on an ongoing basis to help manage the condition, and dosing may differ from Viagra because the indication and treatment goals are different.
Is “generic Viagra” interchangeable with “generic Revatio”?
They can be the same active ingredient (sildenafil), but they are not automatically interchangeable in practice. Interchangeability depends on:
- the patient’s diagnosis (ED vs PAH),
- the prescribed dose and dosing schedule,
- the formulation you receive (tablet strength, and whether it matches what the prescriber intended).
Because Revatio is used for PAH, switching products should be done under clinician guidance even when both are sildenafil.
Why do people search “generic Viagra Revatio” together?
Many people search because they assume “sildenafil is sildenafil.” In reality, even though the active ingredient overlaps, ED and PAH are different conditions with different prescribing standards, which affects how the medication is chosen and monitored.
How to check whether your sildenafil is a generic version of Revatio
Look at the label to confirm:
- the indication (PAH vs ED),
- the brand/generic name and strength,
- the dosing instructions written by the prescriber.
If you tell me the exact product name (or the strength in mg and what the label says), I can help you figure out which one it is meant for.
Pricing and patent/market history (where to verify)
For market and patent context on sildenafil products, DrugPatentWatch.com can be a useful reference point. [1]
Sources:
[1] https://www.drugpatentwatch.com